Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 3/20 | 0.77 |
| ▸ | KIT | P10721 | 1/20 | 0.77 |
| ▸ | MET | P08581 | 17/20 | 0.67 |
| ▸ | KDR | P35968 | 5/20 | 0.66 |
| ▸ | AXL | P30530 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663042 | 0.89 | PDGFRA (0.77) | PDGFRAKITMETKDRAXL | |
| SCHEMBL5054310 | 0.87 | PDGFRA (0.67) | PDGFRAKITMETKDRAXL | |
| SCHEMBL371539 | 0.87 | MET (0.70) | PDGFRAKITMETKDRAXL | |
| SCHEMBL1894552 | 0.87 | PDGFRA (1.00) | PDGFRAKITMETKDRAXL | |
| SCHEMBL12635553 | 0.85 | MET (0.72) | PDGFRAMETKDRAXL | |
| SCHEMBL2744790 | 0.85 | PDGFRA (0.69) | PDGFRAMETKDRAXL | |
| SCHEMBL5056203 | 0.85 | PDGFRA (0.72) | PDGFRAMETKDRAXL | |
| SCHEMBL371814 | 0.84 | MET (0.65) | PDGFRAMETKDRAXL | |
| SCHEMBL21793294 | 0.83 | KDR (0.68) | PDGFRAKITMETKDR | |
| SCHEMBL14279747 | 0.83 | PDGFRA (0.63) | PDGFRAKITMETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| EP-1870414-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | Kirin Pharma Kabushiki Kaisha (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | PDGFRA 52/4885KIT 216/4885MET 1/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | PDGFRA 26/4885KIT 355/4885MET 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.